



RPG LIFE SCIENCES LIMITED
Unit No. 208-213, B Wing,
Bezzola Complex,
Sion-Trombay Road, Chembur,
Mumbai 400071, India
Tel: +91-22-25292152-55
Fax: +91-22-25297423

October 30, 2020

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C-1, G- Block,
Bandra - Kurla Complex, Bandra (East)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Floor 25, P.J. Towers,
Dalal Street,
Mumbai 400 001

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sirs,

Sub: Press Release - Financial Results

Please find enclosed herewith a copy of press release with respect to Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2020.

Kindly take the above on record.

Thanking you,

Yours Sincerely,
For RPG Life Sciences Limited

Rajesh Shirambekar
Head – Legal & Company Secretary



Encl.: as above



**Quarter 2 PBT grew by 22% Y-o-Y and 15% Q-o-Q.
Revenue from operations grew by 6% Q-o-Q.**

Mumbai, 30th October, 2020: RPG Life Sciences Limited has announced its financial results for the second quarter and half year ending on 30th September, 2020.

	YoY Net Revenue from Operations	YoY PBT from Operations
Q2 FY 21 Highlights	Rs 97.13 crores – down from Rs 98.49 crores	Rs 14.73 crores – up from Rs 12.04 crores
H1 FY 21 Highlights	Rs 188.78 crores – down from Rs 192.53 crores	Rs 27.56 crores – up from Rs 22.90 crores

RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted a jump in profits by 22% Y-o-Y and by 15% Q-o-Q for Q2 FY 21, resulting in maintaining the upward trajectory in EBITDA margins, which improved from 16.8% to 19.7% Y-o-Y. Revenue from Operations at Rs 97.13 crores registered a decline of 1% Y-o-Y and a growth of 6% Q-o-Q for Q2 FY 21. For H1 FY 21, too, EBITDA margins improved from 16.7% to 19.3% Y-o-Y despite a decline of 2% Y-o-Y in Revenues from Operations at Rs 188.78 crores.

Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “The overall performance of the Company in the second quarter and first half of this fiscal has been relatively good considering the magnitude of disruptions caused by the extended Covid-19 pandemic. Profits grew by 22% and 20% respectively and EBITDA margins retained their upward trajectory despite a marginal decline in sales Y-o-Y for both Q2 and H1. The revenues grew by 6% Q-o-Q. Focus on profitable product mix, sustained opex control measures and bringing in efficiency in manufacturing operations has helped in improving the overall profitability. Domestic Formulations, the biggest contributor to our business, will continue to be our thrust area. The measures that contributed to our turnaround last year will continue to drive our operations; these measures include product portfolio augmentation, life cycle management of our ‘text book’ brand assets, sales force effectiveness, sales hygiene and opex control.”

RPG Life Sciences Ltd (www.rpglifesciences.com):

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research-based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Enterprises (www.rpggroup.com):

RPG Enterprises, established in 1979, is one of India’s fastest growing business groups with a turnover of US\$ 4 Billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.

Media Contact:

Sumeet Chatterjee

Senior Vice President – Corporate Brand and Group Communications

+91 9820340650 | sumeet@rpg.in

